Invesco
ONCT

Invesco’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Invesco’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-609
Closed -$17K – 4183
2022
Q1 		$17K Sell
609
-14
-2% -$510 ﹤0.01% 3993
2021
Q4 		$28K Sell
623
-72
-10% -$4.84K ﹤0.01% 4015
2021
Q3 		$58K Buy
695
+118
+20% +$9.76K ﹤0.01% 3995
2021
Q2 		$55K Sell
577
-47,320
-99% -$5.62M ﹤0.01% 3947
2021
Q1 		$7.97M Buy
+47,897
New +$6.33M ﹤0.01% 2096
2018
Q3 		– Sell
-1,295
Closed -$2.77M – 3936
2018
Q2 		$2.77M Buy
+1,295
New +$3.28M ﹤0.01% 2537

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return

Invesco's ONCT Position: Q2 2022 in Review

Invesco sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 609 shares — an estimated $17K sold.

Invesco first reported a position in ONCT in Q2 2018 and held it in 6 quarters. The position peaked at $7.97M in Q1 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Invesco reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 609 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $17K.
  • Invesco first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
  • Invesco's Oncternal Therapeutics, Inc. Common Stock position peaked at $7.97M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.